Bone complications of cancer treatment
Cancer Treatment Reviews · 2024-11 · 130 · 102828
DOI: 10.1016/j.ctrv.2024.102828 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-11. Verfasst von Nanxi Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral…. Hauptthemen laut MEDLINE: Bone Neoplasms, Osteonecrosis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 235 Literaturangaben. Gefördert von: Chinese Academy of Meteorological Sciences, National Natural Science Foundation of China, Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
With the advancements in conventional treatment modalities such as radiation, chemotherapy, and surgery, as well as the emergence of immunotherapy, the overall cure rate for solid tumor malignancies has experienced a significant increase. However, it is unfortunate that exposure to cancer treatments can have detrimental effects on the function of osteoblasts and osteoclasts, disturbing bone metabolic homeostasis in patients, as well as causing damage to bone marrow cells and other bone tissues. Consequently, certain tumor treatment options may pose a risk for subsequent bone diseases. Common bone disorders associated with cancer treatment include osteonecrosis, bone loss, and secondary bone tumors. (1)Cancer treatment-related osteonecrosis is primarily linked to the use of radiation therapy and certain chemicals, such as bisphosphonates, denosumab, antiangiogenic agents, and immunomodulators. It has been observed that high-dose radiation therapy is more likely to result in osteonecrosis. (2)Chemicals and hormones, particularly sex hormones, glucocorticoids, and thyroid hormones or thyrotropic hormones, are among the factors that can contribute to cancer treatment-related bone loss. (3)Secondary bone tumors differ from metastases originating from primary tumors, and radiotherapy plays a significant role in their development, while chemotherapy may also exert some influence. Radiogenic secondary bone tumors are predominantly malignant, with osteosarcoma being the most common type. Chemotherapy may be a risk factor for the relatively rare occurrence of secondary Ewing sarcoma of the bone. These treatment-related bone disorders have a considerable adverse impact on the prognosis of cancer patients. Hence, it is imperative to prioritize the bone health of patients undergoing cancer treatment and give it further attention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Si…
Förderung
- Chinese Academy of Meteorological Sciences
- National Natural Science Foundation of China
- Science and Technology Department of Sichuan Province
Zitieren
APA
Zhu, N., Ni, H., Guo, S., Shen, Y. Q., & Chen, Q. (2024). Bone complications of cancer treatment. Cancer Treatment Reviews, 130, 102828. https://doi.org/10.1016/j.ctrv.2024.102828
Vancouver
Zhu N, Ni H, Guo S, Shen YQ, Chen Q. Bone complications of cancer treatment. Cancer Treatment Reviews. 2024;130:102828. doi:10.1016/j.ctrv.2024.102828
BibTeX
@article{Zhu2024,
author = {Zhu, Nanxi and Ni, Hao and Guo, Shengzhao and Shen, Ying-Qiang and Chen, Qianming},
title = {Bone complications of cancer treatment},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {130},
pages = {102828},
doi = {10.1016/j.ctrv.2024.102828}
}
EUVIMED